Improved Clinical Outcomes After FDG-PET Diagnosis Key To Coverage – CMS
This article was originally published in The Gray Sheet
Executive Summary
CMS' decision to deny Medicare coverage of FDG-PET for soft tissue sarcoma and most thyroid cancer indications is consistent with the MCAC recommendation that standards of evidence should not be relaxed for diagnostics of rare diseases